News and Reports
FiercePharma: Novartis CEO opens door to cancer patient demanding 'fair' CAR-T pricing
August 21 Arlene Weintraub David Mitchell had just finished a five-hour infusion of drugs to keep his multiple myeloma under control when he decided to dash off a letter to Joe Jimenez, CEO of Novartis, requesting a meeting about how the company plans to price tisagenlecleucel (CTL019), its CAR-T leukemia treatment expected to win approval […]